New drug trial aims to tame muscle weakness in myasthenia gravis

NCT ID NCT07501702

Recruiting now Disease control Sponsor: Vertex Pharmaceuticals Incorporated Source: ClinicalTrials.gov ↗

First seen Apr 12, 2026 · Last updated May 15, 2026 · Updated 7 times

Summary

This study tests an investigational drug called povetacicept in 30 adults with generalized myasthenia gravis, a condition causing muscle weakness. The goal is to see if the drug safely lowers certain immune proteins (IgG) linked to the disease. Participants receive either the drug or a placebo, and the study lasts several months with a long-term follow-up option.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYASTHENIA GRAVIS, GENERALIZED are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Clinical Trials of South Carolina - Neurology
RECRUITING

Charleston, South Carolina, 29406, United States
Hawaii Pacific Neuroscience
RECRUITING

Honolulu, Hawaii, 96817, United States
Homestead Associates in Research
RECRUITING

Homestead, Florida, 33033, United States
Las Vegas Neurology Center
RECRUITING

Las Vegas, Nevada, 89106, United States
Neurology Offices
RECRUITING

Boca Raton, Florida, 33428, United States
Quantix Research
RECRUITING

Miami, Florida, 33173, United States

Conditions

Explore the condition pages connected to this study.

MYASTHENIA GRAVIS, GENERALIZED